1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 嘉事堂药业股份有限公司 2023 年第一季度报告 证券代码：002462 证券简称：嘉事堂 公告编号：2023-11 嘉事堂药业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： □是 否 1 嘉事堂药业股份有限公司 2023 年第一季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 6.756.081.779.54 | 6. 460. 665. 483. 96 | | 4.57% | ...

Financial Performance - The company's operating revenue for 2022 was CNY 26,219,790,244.85, representing a 2.32% increase compared to CNY 25,625,618,769.65 in 2021[18] - The net profit attributable to shareholders for 2022 was CNY 296,935,789.27, a decrease of 16.09% from CNY 353,876,773.64 in the previous year[18] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 284,354,722.16, down 17.91% from CNY 346,379,731.51 in 2021[18] - The basic earnings per share for 2022 was CNY 1.02, a decline of 15.70% compared to CNY 1.21 in 2021[18] - The total assets at the end of 2022 amounted to CNY 16,556,608,348.72, reflecting a 10.84% increase from CNY 14,937,549,976.72 at the end of 2021[18] - The net assets attributable to shareholders at the end of 2022 were CNY 4,078,022,999.53, which is a 4.93% increase from CNY 3,886,549,170.39 in 2021[18] - The company reported a net cash flow from operating activities of CNY -163,448,296.26, a significant decrease of 117.90% compared to CNY 913,127,423.08 in the previous year[18] - The weighted average return on equity for 2022 was 7.49%, down from 9.42% in 2021[18] - The company reported a net profit of ¥46,831,250 in 2022, while the net cash flow from operating activities was -¥16,344,830, indicating a significant discrepancy of ¥63,176,080[63] - The company reported a total revenue of 440.1 million in 2022, a decrease of 20.5% compared to 2021[102] - The net profit for 2022 was 86.53 million, down from 259.6 million in 2021, representing a decline of 66.7%[102] Revenue Breakdown - The pharmaceutical wholesale segment generated CNY 24.16 billion, accounting for 92.14% of total revenue, but saw a decline of 1.48% compared to the previous year[44] - The company’s logistics revenue was CNY 284 million, which is a decrease of 21.92% year-on-year[46] - The retail pharmacy segment reported revenue of CNY 1.78 billion, marking a significant increase of 39.92% compared to 2021[46] - The company’s Beijing region revenue increased by 9.66% to CNY 10.55 billion, while other regions saw a decline of 9.66%[44] Strategic Initiatives - The company is actively expanding its e-commerce business, resulting in noticeable revenue growth in the retail segment[35] - The company is focusing on optimizing product structure and expanding new product lines in response to industry policy changes, indicating strategic adaptability[33] - The company aims to maintain and enhance its market share in pharmaceuticals and medical devices, focusing on high-quality development in 2023[80] - The company plans to optimize and expand its new health-related business segments, including rehabilitation products and health foods, to counteract pricing pressures[80] - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with a budget of up to 300 million RMB for potential targets[123] Governance and Compliance - The company emphasizes the importance of risk management and compliance, integrating risk management into all operational aspects[81] - The company has a structured governance framework that complies with relevant laws and regulations, ensuring the protection of shareholder rights[85] - The company has established a performance evaluation and incentive mechanism to enhance operational efficiency[91] - The company maintains a complete and independent financial accounting system, complying with accounting standards and ensuring independent financial decision-making[97] - The company has implemented a robust internal control system to support its financial management and decision-making processes[97] Leadership Changes - There were significant changes in the board, with multiple directors resigning due to term completion, including Sun Jianxin and Xu Shuai[103][104] - The company has undergone significant changes in its board and supervisory roles, with multiple appointments and departures effective December 14, 2022[111] - Huang Yibin has been elected as the President and Director of the company since December 14, 2022[112] - The company is focusing on expanding its management team with professionals from diverse backgrounds, enhancing its operational capabilities[112][113][114][115] Employee and Remuneration - The total remuneration for directors, supervisors, and senior management in 2022 amounted to CNY 158.70 million[132] - The chairman, Xu Wenli, received a total pre-tax remuneration of CNY 39.88 million in 2022[134] - The total pre-tax remuneration for the president, Huang Yibin, was CNY 18.04 million[134] - The company’s remuneration management system was approved by the board of directors and is based on performance evaluations[131] Social Responsibility and Community Engagement - 嘉事堂药业在2022年为乡村卫生室免除运费送药数千笔，服务近2000家乡村卫生室[165] - 公司在2022年定点帮扶资金划转至集团定点帮扶专户为湖南定点帮扶县提供50万元支持[166] - 嘉事堂药业在2022年积极落实乡村振兴工作，承担国企社会责任[161] Environmental Compliance - 嘉事堂药业在2022年未因环境问题受到行政处罚，保持良好的环境合规记录[159] - 公司倡导绿色办公，鼓励节水节电和资源回收，推动可持续发展[159]

嘉事堂药业股份有限公司 关于举办 2022 年年度报告网上业绩说明会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 嘉事堂药业股份有限公司（以下简称"嘉事堂"或"公司"）第七届董事 会第二次会议通过了《2022 年年度报告全文及其摘要》,并登载于 2023 年 4 月 21 日的《中国证券报》、《证券时报》和巨潮资讯网(www.cninfo.com.cn）。 欢迎广大投资者积极参与本次网上说明会。 股票代码：002462 股票简称：嘉事堂 公告编号：2023-09 （问题征集专题页面二维码） 公司定于 2023 年 4 月 27 日（星期四）15:00-17:00 在全景网举办 2022 年 度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说 明会。 出席本次说明会的人员有：公司董事长续文利先生、总裁黄奕斌先生、副 总裁林军先生、副总裁王文鼎先生（代行董秘职责）、独立董事梁雨先生。 为充分尊重投资者、提升交流的针对性，现就公司 2021 年度业 ...

Financial Performance - Revenue for Q3 2022 reached ¥7,574,345,325.09, an increase of 11.57% year-over-year[5] - Net profit attributable to shareholders was ¥77,635,692.64, a decrease of 14.17% compared to the same period last year[5] - Basic earnings per share for the quarter was ¥0.27, reflecting a slight increase of 0.30% year-over-year[5] - Total operating revenue for the period reached ¥20,280,780,046.14, an increase of 4.8% compared to ¥19,350,905,221.84 in the previous period[15] - Net profit for the period was ¥399,270,710.90, a decrease of 14.5% from ¥466,993,621.42 in the same period last year[17] - Earnings per share (EPS) for the period was ¥0.85, down from ¥0.91 in the previous period[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥15,750,748,213.30, representing a growth of 5.44% from the end of the previous year[5] - Total assets as of September 30, 2022, amounted to CNY 15,750,748,213.30, an increase from CNY 14,937,549,976.72 at the beginning of the year[12] - Current assets totaled CNY 14,170,834,228.51, up from CNY 13,285,290,480.49 at the beginning of the year[12] - Total liabilities as of September 30, 2022, were CNY 9,893,924,842.00, compared to CNY 9,280,992,337.21 at the beginning of the year[13] - The total assets and liabilities amounted to ¥15,750,748,213.30, compared to ¥14,937,549,976.72 in the previous period[14] Cash Flow - Cash flow from operating activities showed a net outflow of ¥727,857,246.57, a significant decrease of 507.21% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥727,857,246.57, compared to a net inflow of ¥178,741,693.17 in the prior period[19] - The net cash flow from investment activities was -23,465,884.68, compared to -38,320,605.14 in the previous year, indicating an improvement[20] - Cash inflow from financing activities totaled 3,797,361,570.29, up from 3,094,074,447.25 year-over-year[20] - The net cash flow from financing activities was 137,790,671.64, a significant recovery from -440,398,843.78 in the same quarter last year[20] - The total cash and cash equivalents at the end of the period were 1,587,459,695.91, slightly up from 1,578,790,810.05 year-over-year[20] - Cash inflow from borrowing was 3,701,428,927.91, compared to 2,808,000,000.00 in the previous year, reflecting increased leverage[20] - The company had cash outflows for debt repayment amounting to 3,418,388,925.89, compared to 3,054,571,061.81 in the previous year[20] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 22,806[10] - The total equity attributable to shareholders of the parent company increased to ¥4,030,742,909.75 from ¥3,886,549,170.39[14] Operational Highlights - Trade receivables decreased by 54%, primarily due to the maturity and payment of received bills[9] - The company reported a 41% increase in asset disposal gains, attributed to higher asset disposal revenues[9] - Government subsidies received increased by 79.8%, contributing to the rise in non-operating income[9] - The company plans to expand its new business operations, as indicated by a 35% increase in prepayments[9] - The company reported a significant increase in research and development expenses, totaling ¥2,715,829.05 for the period[15] - The company experienced a credit impairment loss of ¥50,846,208.46, compared to ¥13,569,941.97 in the previous period[17] - The company aims to enhance market expansion and product development strategies in the upcoming quarters[18] Financing Activities - Cash received from borrowings increased by 31.8%, primarily due to an increase in borrowings during the period[10] - Other financing cash received decreased by 77.2%, as the required funds were fully obtained from banks, reducing the need for alternative financing[10] - Other financing cash paid decreased by 83.5%, mainly due to a reduction in cash that needed to be repaid[10] Audit Information - The company did not conduct an audit for the third quarter report[21]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥12,706,434,721.05, representing a 1.15% increase compared to ¥12,561,786,991.15 in the same period last year[20]. - The net profit attributable to shareholders decreased by 3.24% to ¥169,486,663.20 from ¥175,169,586.50 year-on-year[20]. - Basic earnings per share decreased by 3.33% to ¥0.58 from ¥0.60 in the same period last year[20]. - The company reported a total profit for the first half of 2022 of ¥342,968,680.24, down 20.29% from ¥430,764,218.24 in the same period of 2021[118]. - The net profit attributable to the parent company was ¥169,486,663.20, a decrease of 3.91% from ¥175,169,586.50 in the previous year[119]. - The total comprehensive income for the period was 891.94 million yuan, a decrease of 9.3% compared to the previous period[130]. - The net profit attributable to shareholders was 227.88 million yuan, representing a decrease of 8.8% compared to the same period last year[130]. Cash Flow and Liquidity - The net cash flow from operating activities turned negative at -¥1,157,613,569.68, a significant decline of 1,552.60% compared to ¥79,692,687.05 in the previous year[20]. - Cash and cash equivalents decreased to ¥1,511,098,250, representing 3.87% of total assets, down from 9.85% last year, a decrease of 5.80%[38]. - The company reported a net cash flow from financing activities of 353,607,134.16 yuan in the first half of 2022, a turnaround from -597,580,668.91 yuan in the same period of 2021[125]. - The total cash inflow from financing activities increased to 2,319,745,425.01 yuan in the first half of 2022, up from 1,856,960,954.54 yuan in the previous year, indicating a growth of approximately 24.8%[125]. - The cash inflow from operating activities totaled 13,756,202,690.70 yuan in the first half of 2022, down from 14,177,461,036.49 yuan in the first half of 2021, indicating a decrease of about 3.0%[124]. Assets and Liabilities - Total assets increased by 2.74% to ¥15,346,471,417.04 from ¥14,937,549,976.72 at the end of the previous year[20]. - Accounts receivable increased to ¥8,221,038,900, accounting for 53.57% of total assets, up from 52.13% last year, an increase of 1.44%[38]. - Inventory rose to ¥2,658,145,320, making up 17.32% of total assets, compared to 14.63% last year, an increase of 2.69%[38]. - Short-term borrowings increased to ¥4,234,737,540, representing 27.59% of total assets, up from 24.88% last year, an increase of 2.71%[39]. - Current liabilities totaled ¥9,335,134,102.02 as of June 30, 2022, compared to ¥9,021,803,540.14 at the start of the year, marking an increase of about 3.49%[111]. Operational Highlights - The pharmaceutical wholesale segment generated ¥11.68 billion, accounting for 91.94% of total revenue, but saw a decline of 3.14% compared to the previous year[34]. - The retail pharmacy segment experienced significant growth, with revenue increasing by 113.75% to ¥875.45 million, representing 6.89% of total revenue[34]. - The company successfully secured distribution qualifications for 67 out of 78 products in the ongoing national bulk procurement program, enhancing its competitive edge[29]. - The company has expanded its e-commerce business model in the health sector, achieving growth despite adverse macroeconomic conditions[28]. - The company is actively developing new medical service businesses, with rehabilitation hospitals in Chengdu, Bengbu, and Shenzhen already completed and operational[28]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company plans to enhance its product structure and regional layout to mitigate the impact of price reductions in pharmaceuticals and medical supplies[54]. - The company is focusing on digital transformation, including the development of smart healthcare and online pharmaceutical distribution[63]. - The company plans to expand its market presence by launching new products in the second half of the year[131]. - The company aims to enhance its operational efficiency by implementing new technologies and optimizing existing processes[135]. Risks and Challenges - The company has acknowledged potential risks related to industry competition, management, market conditions, and national policies[3]. - The company reported a decrease in the weighted average return on equity to 4.12% from 4.71% year-on-year[20]. - The company experienced a credit impairment loss of CNY 2,034,967.95, compared to a gain of CNY 385,909.71 in the same period of 2021[122]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 24,029[95]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of shares, totaling 41,876,430 shares[95]. - The total number of unrestricted sale condition shares is 250,526,315, representing 85.88% of total shares[92]. - The company has not implemented any share buyback or reduction during the reporting period[93]. Compliance and Governance - The semi-annual financial report was not audited[70]. - The financial report complies with the requirements of the enterprise accounting standards, reflecting the financial position and operating results as of June 30, 2022[153]. - The financial statements are prepared based on the going concern principle and historical cost, except for certain financial instruments[150].

Financial Performance - The company's revenue for Q1 2022 was CNY 6,460,665,483.96, representing an increase of 11.19% compared to CNY 5,810,550,826.94 in the same period last year[3] - Net profit attributable to shareholders decreased by 3.65% to CNY 78,838,414.53 from CNY 81,829,097.05 year-on-year[3] - The total revenue for the first quarter was approximately CNY 6.76 billion, a slight decrease from CNY 6.82 billion in the previous year, representing a decline of about 1%[18] - The net profit for the first quarter was CNY 121.40 million, down from CNY 144.89 million year-over-year, indicating a decrease of approximately 16%[17] - Operating profit decreased to ¥167,149,109.01 from ¥199,285,946.50, indicating a decline of 16.1%[16] - The basic earnings per share for the first quarter was CNY 0.27, slightly lower than CNY 0.28 in the previous year[17] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -681,528,106.88, a decline of 415.95% compared to CNY 215,705,560.04 in the previous year[3] - The cash flow from operating activities showed a net outflow of CNY 681.53 million, compared to a net inflow of CNY 215.71 million in the same period last year[20] - Cash and cash equivalents at the end of the period were ¥1,905,282,390.45, down 18.6% from ¥2,338,121,461.75 at the beginning of the year[12] - The company reported a cash and cash equivalents balance of CNY 1.75 billion at the end of the quarter, down from CNY 1.55 billion at the end of the previous year[20] Assets and Liabilities - Total assets increased by 2.68% to CNY 15,337,191,397.86 from CNY 14,937,549,976.72 at the end of the previous year[3] - Total assets reached ¥15,337,191,397.86, up from ¥14,937,549,976.72, reflecting a growth of 2.7%[14] - Total liabilities increased to ¥9,585,873,663.72 from ¥9,280,992,337.21, marking a rise of 3.3%[14] - Shareholders' equity totaled ¥5,751,317,734.14, compared to ¥5,656,557,639.51, showing an increase of 1.7%[14] Operating Costs and Expenses - Total operating costs amounted to ¥6,301,531,573.16, up from ¥5,636,858,890.89, reflecting a year-over-year increase of 11.7%[16] - The company incurred operating expenses of CNY 7.07 billion, up from CNY 6.21 billion year-over-year, reflecting a rise of approximately 14%[18] - The company recorded a 32.5% decrease in minority shareholders' profit to CNY 42,560,380.10 from CNY 63,058,729.85[7] Other Income and Investments - The company reported a 54.8% increase in other income to CNY 13,935,852.35 due to government subsidies received by subsidiaries[6] - Research and development expenses were reported at ¥863,217.54, indicating ongoing investment in innovation[16] - The company raised CNY 1.23 billion through borrowings, significantly higher than CNY 456 million in the same period last year, indicating increased financing activity[20] - The total cash inflow from financing activities was CNY 1.28 billion, compared to CNY 489.51 million in the previous year, showing a substantial increase[20] - The net cash outflow from investing activities was CNY 6.44 million, compared to CNY 4.31 million in the previous year, indicating increased investment expenditures[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,744[9] - The company has no other non-recurring profit and loss items beyond those reported[5]

Financial Performance - The company's revenue for Q1 2022 was CNY 6,460,665,483.96, representing an increase of 11.19% compared to CNY 5,810,550,826.94 in the same period last year[3] - Net profit attributable to shareholders decreased by 3.65% to CNY 78,838,414.53 from CNY 81,829,097.05 year-on-year[3] - The company's net profit for Q1 2022 was RMB 167,149,109.01, a decrease from RMB 199,285,946.50 in the previous year, indicating a decline of 16.14%[16] - The total revenue for the first quarter was approximately CNY 6.76 billion, a slight decrease from CNY 6.82 billion in the previous year, representing a decline of about 0.95%[19] - The net profit for the first quarter was CNY 121.40 million, down from CNY 144.89 million year-over-year, indicating a decrease of approximately 16.16%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -681,528,106.88, a decline of 415.95% compared to CNY 215,705,560.04 in the previous year[3] - The cash flow from operating activities showed a net outflow of CNY 681.53 million, compared to a net inflow of CNY 215.71 million in the same period last year[19] - Cash and cash equivalents at the end of Q1 2022 were RMB 1,905,282,390.45, down from RMB 2,338,121,461.75 at the beginning of the year, representing a decrease of 18.56%[12] - The company reported a cash and cash equivalents balance of CNY 1.75 billion at the end of the quarter, down from CNY 1.55 billion at the end of the previous year[21] - The company raised CNY 1.23 billion through borrowings, significantly higher than CNY 456 million in the same period last year, indicating a strong financing activity[21] - The total cash inflow from financing activities was CNY 1.28 billion, compared to CNY 489.51 million in the previous year, showing a substantial increase[21] - The company incurred a cash outflow of CNY 970.07 million for debt repayment, which is slightly higher than CNY 929.91 million in the previous year[21] - The net cash flow from investing activities was negative at CNY 6.44 million, worsening from a negative CNY 4.31 million in the previous year[21] Assets and Liabilities - Total assets increased by 2.68% to CNY 15,337,191,397.86 from CNY 14,937,549,976.72 at the end of the previous year[3] - Total liabilities increased to RMB 9,585,873,663.72 from RMB 9,280,992,337.21, indicating a rise of 3.28%[14] - The company's equity attributable to shareholders reached RMB 3,966,293,521.25, up from RMB 3,886,549,170.39, reflecting an increase of 2.05%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,744[9] - The top shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[9] Operational Insights - Total operating costs for Q1 2022 were RMB 6,301,531,573.16, up from RMB 5,636,858,890.89, reflecting a year-over-year increase of 11.74%[16] - The company did not report any new product developments or market expansion strategies in this quarter[3] - Research and development expenses for Q1 2022 were RMB 863,217.54, indicating ongoing investment in innovation[16] - The company reported a significant decrease in the disposal of assets, with asset disposal income dropping by 92.1% to CNY 27,897.69[6] - The company did not report any net profit from subsidiaries under common control during the quarter, consistent with the previous year[18] Inventory and Receivables - Accounts receivable increased to RMB 8,128,526,887.18 from RMB 7,787,339,611.18, marking a rise of 4.39%[12] - Inventory at the end of Q1 2022 was RMB 2,425,479,882.35, up from RMB 2,185,383,123.69, reflecting an increase of 11.01%[12]

嘉事堂药业股份有限公司 2022 年第一季度报告全文 证券代码：002462 证券简称：嘉事堂 公告编号：2022-14 嘉事堂药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 6,460,665,483.96 | 5,810,550,826.94 | 11.19% | | 归属于上市公司股东的净利润（元） | 78,838,414.53 | 81,829,097.05 ...

Financial Performance - The company's operating revenue for 2021 was CNY 25,625,618,769.65, representing a 10.19% increase compared to CNY 23,256,135,891.33 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 353,876,773.64, an increase of 11.43% from CNY 317,585,422.67 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 346,379,731.51, up 10.92% from CNY 312,280,514.92 in 2020[18]. - The basic earnings per share for 2021 was CNY 1.21, reflecting an increase of 11.01% compared to CNY 1.09 in 2020[18]. - The total assets at the end of 2021 amounted to CNY 14,937,549,976.72, a 5.69% increase from CNY 14,133,717,238.25 at the end of 2020[18]. - The net assets attributable to shareholders at the end of 2021 were CNY 3,886,549,170.39, which is a 7.10% increase from CNY 3,628,935,746.35 in 2020[18]. - The net cash flow from operating activities for 2021 was CNY 913,127,423.08, a decrease of 18.10% from CNY 1,114,869,517.58 in the previous year[18]. - The company reported a loss of CNY 7.01 million from other non-operating income and expenses, an improvement from a loss of CNY 10.50 million in 2020[24]. - The total revenue for Jia Shi Tang Pharmaceutical Co., Ltd. in 2021 was CNY 25,625,618,769.65, representing a year-on-year increase of 10.19% compared to CNY 23,256,135,891.33 in 2020[44]. - The net profit for 2021 was CNY 601.88 million, an increase of 1.86% compared to the previous year[41]. Revenue Segmentation - The pharmaceutical wholesale segment generated CNY 23,991,152,990.55, accounting for 93.62% of total revenue, but saw a decline of 3.72% from the previous year[44]. - The pharmaceutical retail segment experienced significant growth, with revenue increasing by 235.26% to CNY 1,270,721,190.54, driven by rapid expansion in e-commerce[47]. - The pharmaceutical logistics segment saw a revenue increase of 51.85% to CNY 363,744,588.56, reflecting growth in this area[47]. Strategic Initiatives - The company focused on enhancing logistics management and third-party business cooperation, which contributed to operational efficiency[31]. - The company continued to optimize its product resources and structure in response to national procurement policies, supporting sales growth[32]. - The company emphasized risk control and management, implementing stricter auditing and receivables management practices[33]. - The company plans to respond to policy changes in drug procurement and enhance business research and management coordination in 2022[74]. - The company aims to strengthen its operational system and establish core operational indicators for sustainable growth in 2022[75]. - The company is actively exploring online business models and implementing key projects to drive new business growth[77]. - The company has established a leadership group for targeted poverty alleviation and rural revitalization projects[148]. Governance and Management - The company maintained independent operations from its controlling shareholder, ensuring no interference in decision-making processes[92]. - The company established effective performance evaluation and incentive mechanisms, continuously improving them[88]. - The company ensured transparent information disclosure, complying with relevant laws and regulations to provide accurate and timely information to shareholders[90]. - The company has a well-structured organization with a complete procurement, sales, and logistics distribution system[94]. - The company has appointed independent directors to enhance governance and oversight[98]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 10.86 million[117]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for 2022, driven by new product launches and market expansion strategies[99]. - The company is investing in R&D for new technologies, with an allocated budget of 50 million for the development of innovative pharmaceutical products[99]. - Market expansion efforts include entering three new regional markets, aiming for a 10% market share in each by the end of 2022[99]. - A new product line is set to launch in Q3 2022, expected to contribute an additional 30 million in revenue[99]. - The management team has undergone changes, with the appointment of new executives to strengthen leadership and operational efficiency[100]. Social Responsibility and Community Engagement - The company actively participates in rural revitalization efforts, aligning with national policies and providing quality medical services[145]. - The company has allocated 500,000 RMB for targeted assistance funds to support designated poverty alleviation counties in Hunan[151]. - The company has implemented a "green office" initiative to promote energy conservation and resource recycling[143]. - The company emphasizes social responsibility through practical actions in community support and public welfare[145]. Shareholder Information - The total number of shares is 291,707,100, with 14.59% being restricted shares and 85.41% being unrestricted shares[185]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,430 shares[187]. - The company has 23,685 total shareholders at the end of the reporting period[187]. - The company did not issue any new shares or conduct any stock splits during the reporting period[186]. - The controlling shareholder has committed to not transferring shares acquired through this transaction for 36 months following the issuance[192].

Financial Performance - The company's revenue for Q3 2021 was ¥6,789,118,230.69, representing a year-on-year increase of 3.23%[3] - The net profit attributable to shareholders for Q3 2021 was ¥90,449,294.09, a decrease of 17.25% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥88,418,320.32, down 17.96% year-on-year[3] - The basic earnings per share for Q3 2021 was ¥0.30, a decrease of 18.08% compared to the same period last year[3] - Total operating revenue for the current period reached ¥19,350,905,221.84, an increase of 18.9% compared to ¥16,288,560,957.27 in the previous period[18] - Total operating costs amounted to ¥18,733,139,755.97, up 19.5% from ¥15,681,790,040.81 in the prior period[18] - Operating profit for the current period was ¥646,384,309.00, representing a 12.1% increase from ¥576,046,684.31 in the previous period[19] - Net profit for the current period was ¥466,993,621.42, an increase of 7.8% compared to ¥433,168,445.94 in the same period last year[19] - The company reported a basic earnings per share of ¥0.91, up from ¥0.84 in the previous period[20] - Other income increased to ¥25,286,954.89 from ¥16,174,470.91 in the previous period, reflecting a growth of 56.5%[19] Cash Flow - The operating cash flow for the year-to-date period was ¥178,741,693.17, reflecting a significant decline of 46.68%[3] - Cash flow from operating activities totaled ¥21,361,860,431.16, compared to ¥17,877,382,937.26 in the previous period[21] - Cash flow from investing activities resulted in a net outflow of ¥38,320,605.14, improving from a net outflow of ¥58,224,041.63 in the prior period[23] - Cash flow from financing activities showed a net outflow of ¥440,398,843.78, slightly worse than the net outflow of ¥421,018,996.99 in the previous period[24] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥14,367,033,204.67, an increase of 1.65% from the end of the previous year[3] - Current assets totaled CNY 12,815,086,837.49, compared to CNY 12,567,156,348.84 at the end of 2020, reflecting a growth of approximately 1.97%[14] - Total liabilities stood at CNY 8,821,235,830.29, slightly up from CNY 8,809,686,211.29, indicating a marginal increase[15] - The company's equity attributable to shareholders increased by 4.67% to ¥3,798,291,277.34 compared to the end of the previous year[4] - The company's equity attributable to shareholders reached CNY 3,798,291,277.34, up from CNY 3,628,935,746.35, marking an increase of about 4.67%[16] - The company reported a decrease in short-term borrowings to CNY 3,470,540,955.19 from CNY 3,558,263,244.51, a reduction of approximately 2.5%[15] Inventory and Receivables - Accounts receivable increased to CNY 8,010,878,527.55 from CNY 7,648,002,240.45, representing a growth of approximately 4.75%[14] - Inventory increased to CNY 2,107,667,945.24 from CNY 2,013,591,273.23, reflecting a growth of about 4.67%[14] Government Subsidies and Other Income - The company received government subsidies totaling ¥5,779,473.04 during the reporting period, which is part of the non-recurring gains[6] - The company reported a 56.34% increase in other income due to higher government tax refunds received[8] Compliance and Reporting - The third quarter report of Jia Shitang Pharmaceutical Co., Ltd. is unaudited[25] - The company implemented new leasing standards starting from 2021, with no adjustments made to prior comparative data[25] - The board of directors announced the financial report on October 23, 2021[25] - There are no adjustments to the financial statements related to the new leasing standards for the first year of implementation[25] - The company did not apply retrospective adjustments for prior comparative data under the new leasing standards[25] - The financial report does not include any significant user data or performance guidance[25] - There are no mentions of new product development or market expansion strategies in the report[25] - The report does not indicate any mergers or acquisitions planned by the company[25] - The company has not disclosed any new strategies in the financial report[25] - The report is focused solely on compliance with new accounting standards without detailed financial performance metrics[25]